Tissue distribution of pretomanid in rat brain via mass spectrometry imaging

Xenobiotica

Volumn 46, Issue 3, 2016, Pages 247-252

  Shobo, Adeola ^a   Bratkowska, Dominika ^a   Baijnath, Sooraj ^a   Naiker, Suhashni ^a   Somboro, Anou M ^a   Bester, Linda A ^a   Singh, Sanil D ^a   Naicker, Tricia ^a   Kruger, Hendrik G ^a   Govender, Thavendran ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Drug distribution; MALDI MSI; nitroimidazole

Indexed keywords

PRETOMANID; PRODRUG; 2-NITRO-6-(4-(TRIFLUOROMETHOXY)BENZYLOXY)-6,7-DIHYDRO-5H-IMIDAZO(2,1-B)(1,3)OXAZINE; NITROIMIDAZOLE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; CORPUS CALLOSUM; DRUG DISTRIBUTION; FEMALE; LEFT HEMISPHERE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NERVE CELL NETWORK; NONHUMAN; RAT; RIGHT HEMISPHERE; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; ANIMAL; BLOOD BRAIN BARRIER; BRAIN; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; ANTITUBERCULAR AGENTS; BLOOD-BRAIN BARRIER; BRAIN; FEMALE; NITROIMIDAZOLES; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TISSUE DISTRIBUTION;

EID: 84955673011     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2015.1067935     Document Type: Article

References (30)

1. Abbott NJ, Patabendige AA, Dolman DE, et al. (2010). Structure and function of the blood-brain barrier. Neurobiol Dis 37:13-25.
2. Aboitiz F, Scheibel AB, Fisher RS, Zaidel E. (1992). Fiber composition of the human corpus callosum. Brain Res 598:143-53.
3. Amstalden van Hove ER, Smith DF, Heeren RMA. (2010). A concise review of mass spectrometry imaging. J Chromatogr A 1217:3946-54.
4. Bratkowska D, Shobo A, Singh S, et al. (2015). Determination of the antitubercular drug PA-824 in rat plasma, lung and brain tissues by liquid chromatography tandem mass spectrometry: application to a pharmacokinetic study. J Chromatogr B 988:187-94.
5. Castellino S. (2012). MALDI imaging MS analysis of drug distribution in tissue: the right time!(?). Bioanalysis 4:2549-51.
6. Dartois V. (2014). The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol 12:159-67.
7. Denny WA, Palmer BD. (2010). The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies. Future Med Chem 2:1295-304.
8. Heeren R. (2014). Getting the picture: the coming of age of imaging MS. Int J Mass Spectrom 279:136-46.
9. Himmelsbach M. (2012). 10years of MS instrumental developments-impact on LC-MS/MS in clinical chemistry. J Chromatogr B 883:3-17.
10. Kaneko R, Wada Y. (2003). Decomposition of protein nitrosothiolsin matrix-assisted laser desorption/ionization and electrospray ionization mass spectrometry. J Mass Spectrom 38:526-30.
11. Lakshminarayana SB, Boshoff HIM, Cherian J, et al. (2014). Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis. PLoS One 9:e105222.
12. Lenaerts AJ, Gruppo V, Marietta KS, et al. (2005). Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 49:2294-301.
13. Levsen K, Schiebel HM, Terlouw JK, et al. (2007). Even-electron ions: a systematic study of the neutral species lost in the dissociation of quasimolecular ions. J Mass Spectrom 42:1024-44.
14. Liu L, Xu Y, Shea C, et al. (2010). Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons. J Med Chem 53:2882-91.
15. Manjunatha U, Boshoff HIM, Barry CE. (2009). The mechanism of action of PA-824. Commun Integr Biol 2:215-18.
16. Matthews PM, Rabiner EA, Passchier J, Gunn RN. (2012). Positron emission tomography molecular imaging for drug development. Br J Clin Pharmacol 73:175-86.
17. McDonnell LA, Römpp A, Balluff B, et al. (2014). Discussion point: reporting guidelines for mass spectrometry imaging. Anal Bioanal Chem 407:2035-45.
18. Mindermann T, Landolt H, Zimmerli W, et al. (1993). Penetration of rifampicin into the brain tissue and cerebral extracellular space of rats. J Antimicrob Chemother 31:731-7.
19. Nau R, Sörgel F, Eiffert H. (2010). Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 23:858-83.
20. Prideaux B, Stoeckli M. (2012). Mass spectrometry imaging for drug distribution studies. J Proteomics 75:4999-5013.
21. Shobo A, Bratkowska D, Baijnath S, et al. (2015). Visualization of time-dependent distribution of rifampicin in rat brain using MALDI MSI and quantitative LCMS/MS. Assay Drug Dev Technol 13:277-84.
22. Solon EG. (2012). Use of radioactive compounds and autoradiography to determine drug tissue distribution. Chem Res Toxicol 25:543-55.
23. Stumpf WE. (2013). Whole-body and microscopic autoradiography to determine tissue distribution of biopharmaceuticals: target discoveries with receptor micro-autoradiography engendered new concepts and therapies for vitamin D. Adv Drug Deliv Rev 65:1086-97.
24. Svatoš A. (2010). Mass spectrometric imaging of small molecules. Trends Biotechnol 28:425-34.
25. Tasneen R, Williams K, Amoabeng O, et al. (2015). Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrob Agents Chemother 59:129-35.
26. Wang L, Xu Y, Liang L, et al. (2014). LC-MS/MS method for the simultaneous determination of PA-824, moxifloxacin and pyrazinamide in rat plasma and its application to pharmacokinetic study. J Pharm Biomed Anal 97:1-8.
27. Williams K, Minkowski A, Amoabeng O, et al. (2012). Sterilizing activities of novel combinations lacking first-and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 56:3114-20.
28. Wong EB, Cohen KA, Bishai WR. (2013). Rising to the challenge: new therapies for tuberculosis. Trends Microbiol 21:493-501.
29. World Health Organization (WHO). (2014). Antimicrobial resistance: global report on surveillance. Report from World Health Organization.
30. Zumla A, Nahid P, Cole ST. (2013). Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 12:388-404.